Company Quick10K Filing
RespireRx Pharmaceuticals
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 4 $5
10-Q 2019-11-19 Quarter: 2019-09-30
10-Q 2019-08-14 Quarter: 2019-06-30
10-Q 2019-05-20 Quarter: 2019-03-31
10-K 2019-04-16 Annual: 2018-12-31
10-Q 2018-11-16 Quarter: 2018-09-30
10-Q 2018-10-15 Quarter: 2018-06-30
10-Q 2018-05-21 Quarter: 2018-03-31
10-K 2018-04-17 Annual: 2017-12-31
10-Q 2017-11-20 Quarter: 2017-09-30
10-Q 2017-08-14 Quarter: 2017-06-30
10-Q 2017-05-19 Quarter: 2017-03-31
10-K 2017-03-31 Annual: 2016-12-31
10-Q 2016-11-14 Quarter: 2016-09-30
10-Q 2016-08-12 Quarter: 2016-06-30
10-Q 2016-05-13 Quarter: 2016-03-31
10-K 2016-03-29 Annual: 2015-12-31
10-Q 2015-11-12 Quarter: 2015-09-30
10-Q 2015-08-13 Quarter: 2015-06-30
10-Q 2015-05-14 Quarter: 2015-03-31
10-K 2015-03-30 Annual: 2014-12-31
10-Q 2015-03-09 Quarter: 2014-09-30
10-Q 2015-02-24 Quarter: 2014-06-30
10-Q 2015-02-10 Quarter: 2014-03-31
10-K 2015-01-06 Annual: 2013-12-31
10-Q 2014-12-15 Quarter: 2013-09-30
10-Q 2014-12-15 Quarter: 2013-06-30
10-Q 2014-11-24 Quarter: 2013-03-31
10-K 2014-10-14 Annual: 2012-12-31
10-Q 2014-07-30 Quarter: 2012-09-30
10-Q 2012-08-16 Quarter: 2012-06-30
10-Q 2012-05-15 Quarter: 2012-03-31
10-Q 2011-11-14 Quarter: 2011-09-30
10-Q 2011-08-18 Quarter: 2011-06-30
10-Q 2011-05-23 Quarter: 2011-03-31
10-K 2011-03-18 Annual: 2010-12-31
10-Q 2010-11-12 Quarter: 2010-09-30
10-Q 2010-08-16 Quarter: 2010-06-30
10-Q 2010-05-17 Quarter: 2010-03-31
10-K 2010-04-08 Annual: 2009-12-31
8-K 2020-03-21 Enter Agreement, Sale of Shares, Other Events, Exhibits
8-K 2020-03-18 Other Events
8-K 2020-03-09 Regulation FD, Exhibits
8-K 2020-03-05 Other Events
8-K 2020-03-02 Enter Agreement, Other Events, Exhibits
8-K 2020-02-12 Regulation FD, Exhibits
8-K 2020-01-28 Officers, Exhibits
8-K 2019-12-16 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-11-04 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-10-22 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-09-09 Regulation FD, Exhibits
8-K 2019-08-19 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-05-17 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-04-24 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-02-27 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2018-12-28 Officers
8-K 2018-12-10 Regulation FD, Exhibits
8-K 2018-12-06 Enter Agreement, Off-BS Arrangement
8-K 2018-09-24
8-K 2018-09-12 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-09-04 Enter Agreement, Other Events, Exhibits
8-K 2018-06-13 Officers, Exhibits
8-K 2018-06-13 Regulation FD, Exhibits
8-K 2018-05-31 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-04-05 Enter Agreement, Off-BS Arrangement, Officers
8-K 2018-01-08 Regulation FD, Exhibits
8-K 2017-12-29

RespireRx Pharmaceuticals Financials

RSPI Metrics, Comps, Filings

Annual | Quarterly

Business

The Company's mission is to develop innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling. We are developing treatment options that address conditions that affect millions of people, but for which there are few or poor treatment options, including obstructive sleep apnea (“OSA”), attention deficit hyperactivity disorder (“ADHD”) and recovery from spinal cord injury (“SCI”), as well as certain neurological orphan diseases such as Fragile X Syndrome. RespireRx is developing a pipeline of new drug products based on our broad patent portfolios for two drug platforms: ampakines, proprietary compounds that positively modulate AMPA-type glutamate receptors to promote neuronal function and cannabinoids, including dronabinol (“∆9-THC”).

Since its formation in 1987, RespireRx Pharmaceuticals Inc. (formerly known as Cortex Pharmaceuticals, Inc.) has been engaged in the research and clinical development of a class of proprietary compounds known as ampakines, a term used to designate their actions as positive allosteric modulators of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (“AMPA”) glutamate receptor. Ampakines are small molecule compounds that enhance the excitatory actions of the neurotransmitter glutamate at the AMPA receptor complex, which mediates most excitatory transmission in the central nervous system (“CNS”). These drugs do not have agonistic or antagonistic properties but instead positively modulate the receptor rate constants for transmitter binding, channel opening, and desensitization. We currently are developing two lead clinical compounds, CX717 and CX1739, and one pre-clinical compound, CX1942. These compounds belong to a new class of ampakines that do not display the electrophysiological and biochemical effects that lead to undesirable side effects, namely convulsive activities, previously reported in animal models of earlier generations.

The Company owns patents and patent applications, or the rights thereto, for certain families of chemical compounds, including ampakines, which claim the chemical structures, their actions as ampakines and their use in the treatment of various disorders. Patents claiming a family of chemical structures, including CX1739 and CX1942, as well as their use in the treatment of various disorders extend through at least 2028. Additional patent applications claiming the use of ampakines in the treatment of certain neurological and neuropsychiatric disorders, such as Attention Deficit Hyperactivity Disorder (“ADHD”) have been or are expected to be filed in the near future.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Apex 2 (APEX) 5,204 -109.3 -241% 20 230 0 0 -47 -47 5,184
Timberline Resources (TLRS) 5,122 -3.2 -9% 15,551 1,069 0 0 -1,433 -1,580 5,008
Amarc Resources (AXREF) 5,118 0% 799 1,342 0 0 0 0 4,945
US Rare Earth Minerals (USMN) 5,118 -4.4 -3,599% 33 1,214 0 0 -1,196 -1,169 5,085
Tauriga Sciences (TAUG) 3,947 20% -1.9 -347% 659 432 216 43 -2,286 -2,110 3,917
uSell.com (USEL) 5,104 2% -0.1 -121% 11,276 10,072 74,171 1,568 -13,622 -10,652 1,124
ROI Land Investments (ROII) 5,064 -0.4 -64% 25,790 42,491 0 0 -16,488 -14,985 6,465
Penn Virginia (PVA) 5,004 95% 2.5 6% 1,211,780 695,122 347,299 330,362 67,290 225,983 564,017
Nephros (NEPH) 62,276 58% -14.8 -38% 11,554 4,832 8,942 5,182 -4,384 -4,006 59,300
Innerscope Hearing Technologies (INND) 2,206 57% -0.7 -118% 4,220 8,205 657 372 -4,980 -4,663 3,150
RespireRx Pharmaceuticals (RSPI) 4,849 -3.8 -1,393% 107 7,146 0 0 -1,487 -1,287 4,849
E-Qure (EQUR) 4,836 -10.5 -1,247% 37 320 0 0 -457 -456 4,800
Sterling Consolidated (STCC) 4,728 28% 17.3 0% 7,036 5,715 5,486 1,516 31 272 4,695
Bespoke Extracts (BSPK) 4,689 -17% 1.6 3,249% 79 111 54 -9 2,581 2,938 4,679
Black Cactus Global (BLGI) 4,643 -1.2 -1,386% 286 916 0 0 -3,965 -3,900 4,601
Deep Well Oil & Gas (DWOG) 4,611 -21.7 -1% 22,677 527 0 0 -222 -211 4,577
Advantego (ADGO) 4,600 11% -5.2 -272% 554 4,782 29 3 -1,508 -858 4,465
Biorestorative Therapies (BRTX) 5,455 0% -0.4 -898% 1,458 13,887 98 0 -13,097 -12,936 5,514
Brightlane (BTLN) 4,486 75% -18.4 24,179,200% 83 63 -242 -242 4,449
Amplitech (AMPG) 2,417 51% 128.7 -0% 3,756 2,733 2,018 1,035 -11 25 3,211

Balance Sheet ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash1,6111521416353928533
Accounts Receivable
Inventory
PP&E670171250
Assets1,82119952400146234195124
Accounts Payable
Long-Term Debt337
Liabilities1,1453,1904,2402,6013,0085,7274,5505,857
Stockholders' Equity676-2,992-4,188-2,200-2,862-5,493-4,355-5,733
Income Statement ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue3,1154862870
Cost of Revenue
Gross Profit
R&D2,1888272075921,7073,1761,732688
SG&A3,1891,9479333,8233,6205,2962,5161,488
Tax000000
Net Income-2,255-7,572-1,201-2,708-5,962-9,230-4,291-2,592
Cash Flow ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating-1,936-1,862-182-886-1,296-1,329-697-427
Cash Investing2,031250-18-20
Cash Financing478378451,0531,1891,368690376